AR055953A1 - Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la producion de las mismas - Google Patents

Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la producion de las mismas

Info

Publication number
AR055953A1
AR055953A1 ARP060101986A ARP060101986A AR055953A1 AR 055953 A1 AR055953 A1 AR 055953A1 AR P060101986 A ARP060101986 A AR P060101986A AR P060101986 A ARP060101986 A AR P060101986A AR 055953 A1 AR055953 A1 AR 055953A1
Authority
AR
Argentina
Prior art keywords
hydroxamic acid
procedures
production
same
acid formulations
Prior art date
Application number
ARP060101986A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR055953(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of AR055953A1 publication Critical patent/AR055953A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Composicion farmacéutica o una composicion cristalina con un perfil de disolucion específico, que comprende ácido hidroxámico suberoilanilida o una sal farmacéuticamente aceptable o hidrato del mismo como ingrediente activo, procedimiento para producir dicha composicion cristalina o composicion farmacéutica y composiciones con una distribucion de tamano de partícula específica.
ARP060101986A 2005-05-20 2006-05-17 Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la producion de las mismas AR055953A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68287505P 2005-05-20 2005-05-20
US69312805P 2005-06-23 2005-06-23

Publications (1)

Publication Number Publication Date
AR055953A1 true AR055953A1 (es) 2007-09-12

Family

ID=37452585

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101986A AR055953A1 (es) 2005-05-20 2006-05-17 Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la producion de las mismas

Country Status (20)

Country Link
US (4) US8093295B2 (es)
EP (2) EP2292221A3 (es)
JP (2) JP5264174B2 (es)
KR (2) KR100993135B1 (es)
AR (1) AR055953A1 (es)
AU (3) AU2006249440C1 (es)
BR (1) BRPI0605893A (es)
CA (1) CA2580367C (es)
CR (1) CR8912A (es)
DO (1) DOP2006000113A (es)
EC (1) ECSP077263A (es)
IL (1) IL181070A0 (es)
MA (1) MA28804B1 (es)
MX (1) MX2007002047A (es)
MY (1) MY144613A (es)
NI (1) NI200700031A (es)
NZ (2) NZ594669A (es)
PE (1) PE20061390A1 (es)
TW (2) TWI365068B (es)
WO (2) WO2006127319A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI365068B (en) * 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
CN102264694B (zh) 2008-10-15 2015-11-25 基因里克斯(英国)有限公司 用于制备伏立诺他的方法
WO2010061220A2 (en) * 2008-11-26 2010-06-03 Generics [Uk] Limited Novel processes and pure polymorphs
WO2010061219A2 (en) * 2008-11-26 2010-06-03 Generics [Uk] Limited Polymorphs
US20110313044A1 (en) * 2010-06-18 2011-12-22 Urquima S.A. Polymorphs of Suberoylanilide Hydroxamic Acid
WO2018011811A2 (en) * 2016-07-13 2018-01-18 Rappaport Family Institute For Research In The Medical Sciences Inhibitors of cytoplasmic histone deacetylase 4 complex for treating or preventing vascular or valve calcification
CN107362148B (zh) * 2017-07-27 2020-04-21 东曜药业有限公司 一种治疗肿瘤的药物组合物及其制备方法和应用
US20220354951A1 (en) 2019-08-02 2022-11-10 Onehealthcompany, Inc. Treatment of Canine Cancers

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS61176523A (ja) 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5608108A (en) 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5055608A (en) 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5175191A (en) 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
USRE38506E1 (en) 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
JP3170069B2 (ja) * 1992-10-06 2001-05-28 日水製薬株式会社 徐放性顆粒剤
US6043389A (en) 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6231880B1 (en) 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6262116B1 (en) 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
TR200101049T2 (tr) 1998-10-13 2002-01-21 Fujisawa Pharmaceutical Co. Ltd. Siklik tetrapeptid bileşiği ve kullanımı
CA2366408A1 (en) 1999-05-03 2000-11-30 Methylgene, Inc. Inhibition of histone deacetylase
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
KR20020059393A (ko) 1999-09-08 2002-07-12 제임스 에스. 쿼크 새로운 부류의 세포분화제 및 히스톤 데아세틸라아제, 및이의 사용 방법
US6541661B1 (en) 1999-11-23 2003-04-01 Methylgene, Inc. Inhibitors of histone deacetylase
CA2404002A1 (en) 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
WO2002015921A2 (en) 2000-08-18 2002-02-28 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
JP4975941B2 (ja) 2000-09-29 2012-07-11 トポターゲット ユーケー リミテッド （ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途
AU2002243231A1 (en) 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6495719B2 (en) 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US7314953B2 (en) 2001-03-27 2008-01-01 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
AU2002318364A1 (en) 2001-06-14 2003-01-02 Bristol-Myers Squibb Company Novel human histone deacetylases
WO2003032921A2 (en) 2001-10-16 2003-04-24 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
US20040132643A1 (en) 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
WO2003070188A2 (en) 2002-02-15 2003-08-28 Sloan-Kettering Institute For Cancer Research Method of treating trx mediated diseases
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
ES2532607T3 (es) 2002-03-04 2015-03-30 Merck Hdac Research, Llc Métodos de inducción de la diferenciación terminal
US20070060614A1 (en) 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US20060276547A1 (en) 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
CN100566711C (zh) 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
DE10218106A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
CN1839121A (zh) 2003-04-01 2006-09-27 斯隆-凯特林癌症研究所 异羟肟酸化合物及其使用方法
DE602004026321D1 (de) * 2003-08-26 2010-05-12 Merck Hdac Res Llc Verwendung von SAHA zur Behandlung von Mesotheliom
TWI365068B (en) * 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
US20090227674A1 (en) 2005-08-18 2009-09-10 Richon Victoria M Combination methods fo saha and targretin for treating cancer
CA2626679C (en) 2005-11-04 2011-08-16 Merck & Co., Inc. Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies
AU2006311808A1 (en) 2005-11-04 2007-05-18 Merck Sharp & Dohme Corp. Methods of using SAHA and bortezomib for treating cancer
AU2006311820A1 (en) 2005-11-04 2007-05-18 Merck Sharp & Dohme Corp. Methods of using SAHA and erlotinib for treating cancer

Also Published As

Publication number Publication date
KR20070062505A (ko) 2007-06-15
KR20080113135A (ko) 2008-12-26
CA2580367A1 (en) 2006-11-30
CA2580367C (en) 2012-08-21
US8093295B2 (en) 2012-01-10
CR8912A (es) 2008-02-21
NZ594669A (en) 2013-02-22
US8288440B2 (en) 2012-10-16
IL181070A0 (en) 2007-07-04
EP2292221A3 (en) 2011-08-10
WO2006127319A2 (en) 2006-11-30
TW200727892A (en) 2007-08-01
MY144613A (en) 2011-10-04
AU2009201652A1 (en) 2009-05-21
MX2007002047A (es) 2007-04-12
JP2008519081A (ja) 2008-06-05
PE20061390A1 (es) 2007-01-15
AU2009201650B2 (en) 2011-09-15
US20100112046A1 (en) 2010-05-06
AU2009201650A1 (en) 2009-05-21
TW201034660A (en) 2010-10-01
JP2011251985A (ja) 2011-12-15
TWI365068B (en) 2012-06-01
DOP2006000113A (es) 2006-10-31
JP5264174B2 (ja) 2013-08-14
WO2006127321A2 (en) 2006-11-30
EP1853245A2 (en) 2007-11-14
AU2009201652B2 (en) 2011-10-06
MA28804B1 (fr) 2007-08-01
US8450372B2 (en) 2013-05-28
TWI415603B (zh) 2013-11-21
AU2010201359A1 (en) 2010-04-29
WO2006127321A3 (en) 2007-03-22
US20100113829A1 (en) 2010-05-06
JP5308486B2 (ja) 2013-10-09
AU2006249440C1 (en) 2009-08-13
NZ553204A (en) 2011-09-30
NI200700031A (es) 2008-03-03
ECSP077263A (es) 2007-04-26
EP2292221A2 (en) 2011-03-09
US20100119596A1 (en) 2010-05-13
AU2006249440B2 (en) 2009-03-12
KR100993135B1 (ko) 2010-11-10
US20080132575A1 (en) 2008-06-05
WO2006127319A3 (en) 2007-03-29
AU2006249440A1 (en) 2006-11-30
KR100884500B1 (ko) 2009-02-20
BRPI0605893A (pt) 2007-12-18

Similar Documents

Publication Publication Date Title
AR055953A1 (es) Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la producion de las mismas
BR112014024833A8 (pt) Produto farmacêutico veterinário mastigável macio, processo para a fabricação de um produto, uso de ácido pamóico ou um sal farmaceuticamente aceitável do mesmo, uso de um produto farmacêutico veterinário mastigável macio, e, composição farmacêutica veterinária mastigável macia.
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
BR112012030818A2 (pt) "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv"
AR058679A1 (es) Preparacion farmaceutica que contiene meloxicam
DOP2006000170A (es) Nuevos derivados de espirocromanona
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
UY32599A (es) Formulación oral sólida de abt-263
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
AR095159A2 (es) Una composición farmacéutica en forma de cápsula para administración oral
PE20140255A1 (es) Tableta dispersable en forma oral
EA201490653A1 (ru) Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств
CY1122596T1 (el) Νεες φαρμακοτεχνικες μορφες (τριμεθοξυφαινυλαμινο)πυριμιδινυλιου
BR112014009910A2 (pt) formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
IN2014DN09347A (es)
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
BR112015010271A8 (pt) produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos
EP2722042A4 (en) INDANONE DERIVATIVES, THEIR OPTICAL ISOMERS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES
CO6592109A2 (es) Nueva forma cristalina de un derivado de ciclopropilbenzamida
BR112014008783A2 (pt) compostos para o tratamento e profilaxia da doença causada por vírus sincicial respiratório
RU2014129620A (ru) Композиции, содержащие аморфный эмодепсид
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
WO2009084041A3 (en) Pharmaceutical compositions of dexibuprofen
CL2016000183A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación

Legal Events

Date Code Title Description
FC Refusal